Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

PRMEPrime Medicine, Inc.

Nasdaq · CIK 0001894562
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts215

Identity from submissions API

NamePrime Medicine, Inc.
CIK0001894562
TickersPRME
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN000000000
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone617-465-0013
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
60 FIRST ST.
CAMBRIDGE
MA
02141
MA
Mailing address
60 FIRST ST.
CAMBRIDGE
MA
02141
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

306 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-13 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001193125-26-460600 005-93800 261552316 34 25322
2026-11-13 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-126830 005-93800 261550672 34 13073
2026-11-12 10-Q 10-Q 0001628280-26-073392 001-41536 261547064 34 5395826 1 1
2026-11-12 8-K 8-K 2.02 0001628280-26-073372 001-41536 261546831 34 233961 1 1
2026-11-12 8-K 8-K 1.01 0001628280-26-073131 001-41536 261543461 34 501422 1 1
2026-11-12 424B5 424B5 0001628280-26-073125 333-291348 261543431 33 565260
2026-11-10 424B5 424B5 0001628280-26-072802 333-291348 261541166 33 557524
2026-11-10 8-K 8-K 2.02,8.01,9.01 0001628280-26-072713 001-41536 261540327 34 6818469 1 1
2026-08-06 10-Q 10-Q 0001628280-26-053883 001-41536 261246127 34 5163262 1 1
2026-08-06 8-K 8-K 2.02,9.01 0001628280-26-053878 001-41536 261246116 34 230691 1 1
2026-07-08 8-K 8-K 8.01 0001628280-26-047590 001-41536 261160797 34 140625 1 1
2026-06-08 4 FORM 4 0001628280-26-041579 5484
2026-06-08 4 FORM 4 0001628280-26-041575 5477
2026-06-08 4 FORM 4 0001628280-26-041572 5457
2026-06-08 4 FORM 4 0001628280-26-041569 5487
2026-06-08 4 FORM 4 0001628280-26-041566 5495
2026-06-08 4 FORM 4 0001628280-26-041560 5463
2026-06-08 4 FORM 4 0001628280-26-041553 5467
2026-06-08 8-K 8-K 5.07 0001628280-26-041543 001-41536 261072719 34 185976 1 1
2026-05-07 10-Q 10-Q 0001628280-26-031726 001-41536 26950997 34 4641607 1 1
2026-05-07 8-K 8-K 2.02,9.01 0001628280-26-031719 001-41536 26950980 34 224391 1 1
2026-04-23 ARS ARS 0001628280-26-026704 001-41536 26885792 34 33162820
2026-04-23 DEFA14A DEFA14A 0001628280-26-026701 001-41536 26885745 34 483907
2026-04-23 DEF 14A DEF 14A 0001628280-26-026697 001-41536 26885734 34 1309937 1 1
2026-04-17 4 FORM 4 0001470831-26-000388 5503
2026-04-17 3 FORM 3 0001470831-26-000386 427092
2026-04-16 8-K 8-K 5.02 0001628280-26-025372 001-41536 26865756 34 280012 1 1
2026-03-04 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-000723 333-291348 26724020 33 1721
2026-03-03 S-8 S-8 0001628280-26-013575 333-293959 26711155 33 184503 1 1
2026-03-03 POS AM POS AM 0001894562-26-000009 333-291348 26711144 33 573600
2026-03-03 10-K 10-K 0001628280-26-013569 001-41536 26711119 34 9790035 1 1
2026-03-03 POSASR POSASR 0001894562-26-000007 333-291348 26711111 33 812060 1 1
2026-03-03 8-K 8-K 2.02,7.01,9.01 0001628280-26-013565 001-41536 26711100 34 6603016 1 1
2026-02-27 4 FORM 4 0001628280-26-012893 5410
2026-02-24 4 FORM 4 0001628280-26-011208 5391
2026-02-24 4 FORM 4 0001628280-26-011181 5435
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001897612-26-000293 005-93800 26637804 34 7515
2026-01-12 8-K 8-K 7.01,9.01 0001628280-26-001773 001-41536 26524821 34 6528915 1 1
2025-11-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001897612-25-000555 005-93800 251483388 34 7308
2025-11-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001845041-25-000005 005-93800 251473423 34 40534
2025-11-07 S-3ASR S-3ASR 0001628280-25-050428 333-291348 251460585 33 1791099 1 1
2025-11-07 10-Q 10-Q 0001628280-25-050422 001-41536 251460527 34 5911602 1 1
2025-11-07 8-K 8-K 2.02,9.01 0001628280-25-050415 001-41536 251460510 34 229689 1 1
2025-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002807 005-93800 251452743 34 11201
2025-09-08 8-K 8-K 7.01,9.01 0001894562-25-000056 001-41536 251298632 34 6345973 1 1
2025-08-11 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001072613-25-000536 005-93800 251203823 34 61559
2025-08-07 10-Q 10-Q 0001628280-25-038619 001-41536 251191818 34 6312626 1 1
2025-08-07 8-K 8-K 2.02,9.01 0001628280-25-038617 001-41536 251191804 34 232798 1 1
2025-08-05 4 FORM 4 0001894562-25-000051 12613
2025-08-05 4 FORM 4 0001894562-25-000050 12561
2025-08-05 4 FORM 4 0001894562-25-000049 12534
2025-08-05 4 FORM 4 0001894562-25-000048 16657
2025-08-05 4 FORM 4 0001894562-25-000047 20754
2025-08-05 4 FORM 4 0001894562-25-000046 20763
2025-08-05 4 FORM 4 0001894562-25-000045 20730
2025-08-05 4 FORM 4 0001894562-25-000044 12544
2025-08-05 4 FORM 4 0001894562-25-000043 8525
2025-08-05 4 FORM 4 0001894562-25-000042 416632
2025-08-05 8-K 8-K 5.02,5.07 0001628280-25-037840 001-41536 251185333 34 190707 1 1
2025-08-05 4 xslF345X05/form4-08052025_080848.xml 0001415889-25-021025 11114
2025-08-01 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-013462 10423
2025-08-01 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-013461 12574
2025-08-01 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-013460 20345
2025-07-31 8-K 8-K 1.01,9.01 0001628280-25-037076 001-41536 251172742 34 482716 1 1
2025-07-31 424B5 424B5 0001628280-25-037072 333-275321 251172709 33 545717
2025-07-30 424B5 424B5 0001628280-25-036721 333-275321 251167212 33 540709
2025-07-30 8-K 8-K 2.02,8.01,9.01 0001628280-25-036705 001-41536 251166946 34 6325608 1 1
2025-07-15 8-K 8-K 5.02 0001628280-25-034971 001-41536 251124798 34 142455 1 1
2025-07-14 DEF 14A DEF 14A 0001193125-25-158716 001-41536 251122125 34 621988
2025-07-02 PRE 14A PRE 14A 0001193125-25-155000 001-41536 251101975 34 794975
2025-07-01 4 FORM 4 0001628280-25-033754 5162
2025-06-23 4 FORM 4 0001628280-25-032626 5161
2025-06-16 4 FORM 4 0001628280-25-031637 5162
2025-06-12 4 FORM 4 0001628280-25-031045 433985
2025-06-05 4 FORM 4 0001628280-25-029774 435562
2025-06-05 4 FORM 4 0001628280-25-029773 5340
2025-06-05 4 FORM 4 0001628280-25-029772 434307
2025-06-05 4 FORM 4 0001628280-25-029771 435083
2025-06-05 4 FORM 4 0001628280-25-029770 433713
2025-06-05 4 FORM 4 0001628280-25-029769 434494
2025-06-05 4 FORM 4 0001628280-25-029768 435769
2025-06-05 8-K 8-K 5.07,9.01 0001628280-25-029646 001-41536 251027224 34 186440 1 1
2025-05-22 4 FORM 4 0001894562-25-000030 4456
2025-05-22 4 FORM 4 0001894562-25-000028 4458
2025-05-22 4 FORM 4 0001894562-25-000026 5002
2025-05-19 4 FORM 4 0001894562-25-000024 436643
2025-05-19 4 FORM 4 0001894562-25-000023 5405
2025-05-19 DEFA14A DEFA14A 0001193125-25-122158 001-41536 25961814 34 16355311
2025-05-19 8-K 8-K 5.02,7.01,8.01,9.01 0001193125-25-122156 001-41536 25961795 34 16514054 1 1
2025-05-12 4 FORM 4 0001894562-25-000020 434662
2025-05-12 4 FORM 4 0001894562-25-000019 437753
2025-05-12 4 FORM 4 0001894562-25-000018 434180
2025-05-08 10-Q 10-Q 0001628280-25-023486 001-41536 25923998 34 5356081 1 1
2025-05-08 8-K 8-K 2.02,9.01 0001628280-25-023482 001-41536 25923986 34 238486 1 1
2025-04-22 ARS ARS 0001628280-25-018708 001-41536 25854894 34 32100312
2025-04-22 DEFA14A DEFA14A 0001628280-25-018706 001-41536 25854884 34 483243
2025-04-22 DEF 14A DEF 14A 0001628280-25-018704 001-41536 25854875 34 751504
2025-03-18 8-K 8-K 7.01,8.01,9.01 0001193125-25-056122 001-41536 25746486 34 18713407 1 1
2025-03-04 4 FORM 4 0001894562-25-000014 5443
2025-03-03 4 FORM 4 0001894562-25-000012 5440
2025-03-03 4 FORM 4 0001894562-25-000010 5425
2025-03-03 4 FORM 4 0001894562-25-000008 5410
2025-03-03 4 FORM 4 0001894562-25-000006 5399
2025-03-03 4 FORM 4 0001894562-25-000004 5409
2025-03-03 4 FORM 4 0001894562-25-000002 5415
2025-02-28 S-8 S-8 0001628280-25-008885 333-285396 25682858 33 100200
2025-02-28 10-K 10-K 0001628280-25-008884 001-41536 25682824 34 17872579 1 1
2025-02-28 8-K 8-K 2.02,9.01 0001628280-25-008873 001-41536 25682800 34 237457 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001493152-25-006876 005-93800 25628935 34 10952
2025-01-13 8-K 8-K 7.01,9.01 0001628280-25-001244 001-41536 25524879 34 6224703 1 1
2024-12-20 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-24-003900 333-283780 241569588 33 1716
2024-12-18 CORRESP filename1.htm 0001193125-24-281271 6436
2024-12-17 UPLOAD filename1.pdf 0000000000-24-013902 333-283780 39901
2024-12-13 S-3 S-3 0001628280-24-051126 333-283780 241546871 33 287745
2024-12-09 4 FORM 4 0001894562-24-000049 5675
2024-12-09 4 FORM 4 0001894562-24-000048 5535
2024-12-09 4 FORM 4 0001894562-24-000047 5544
2024-11-22 SC 13D/A ARCH VENTURE FUND XII, L.P. - PRIME MEDICINE -- SCH 13D/A(#1) 0001072613-24-000898 005-93800 241491086 34 437591
2024-11-12 10-Q 10-Q 0001628280-24-047130 001-41536 241448159 34 7049017 1 1
2024-11-12 8-K 8-K 2.02,9.01 0001628280-24-047119 001-41536 241448028 34 240396 1 1
2024-11-12 SC 13G/A filing.txt 0000315066-24-002848 005-93800 241444970 34 7757
2024-10-24 8-K 8-K 7.01,9.01 0001628280-24-043500 001-41536 241390783 34 186516 1 1
2024-10-10 4 FORM 4 0001894562-24-000043 8568
2024-10-04 SC 13G SC 13G 0001140361-24-042895 005-93800 241355158 34 51826
2024-09-30 8-K 8-K 1.01,3.02,7.01,9.01 0001628280-24-041541 001-41536 241336686 34 7179514 1 1
2024-08-08 10-Q 10-Q 0001628280-24-035893 001-41536 241186218 34 5040873 1 1
2024-08-08 8-K 8-K 2.02,9.01 0001628280-24-035886 001-41536 241186180 34 228286 1 1
2024-06-14 4 FORM 4 0001894562-24-000041 5348
2024-06-14 4 FORM 4 0001894562-24-000040 5355
2024-06-14 4 FORM 4 0001894562-24-000039 5328
2024-06-14 4 FORM 4 0001894562-24-000038 5358
2024-06-14 4 FORM 4 0001894562-24-000037 5367
2024-06-14 4 FORM 4 0001894562-24-000036 5335
2024-06-14 4 FORM 4 0001894562-24-000035 5339
2024-06-12 8-K 8-K 5.03,5.07,9.01 0001628280-24-027816 001-41536 241038515 34 230839 1 1
2024-06-07 4 FORM 4 0001894562-24-000026 8550
2024-05-21 4 FORM 4 0001894562-24-000024 5539
2024-05-21 4 FORM 4 0001894562-24-000023 5527
2024-05-21 4 FORM 4 0001894562-24-000022 5520
2024-05-21 DEFA14A DEFA14A 0001628280-24-024535 001-41536 24969350 34 35772
2024-05-21 8-K 8-K 5.03,9.01 0001628280-24-024530 001-41536 24969241 34 339030 1 1
2024-05-10 10-Q 10-Q 0001628280-24-022473 001-41536 24932954 34 4696256 1 1
2024-05-10 8-K 8-K 2.02,9.01 0001628280-24-022466 001-41536 24932937 34 239638 1 1
2024-04-29 ARS ARS 0001628280-24-018992 001-41536 24890681 34 33496991
2024-04-29 DEFA14A DEFA14A 0001628280-24-018983 001-41536 24890574 34 503590
2024-04-29 DEF 14A DEF 14A 0001628280-24-018977 001-41536 24890543 34 791412
2024-04-19 PRE 14A DEF 14A 0001628280-24-016946 001-41536 24857803 34 722521
2024-03-04 4 FORM 4 0001894562-24-000018 5284
2024-03-01 S-8 S-8 0001628280-24-008117 333-277567 24707045 33 98786
2024-03-01 10-K 10-K 0001628280-24-008116 001-41536 24707034 34 18813550 1 1
2024-03-01 8-K 8-K 2.02,9.01 0001628280-24-008113 001-41536 24707021 34 237806 1 1
2024-02-29 3 xslF345X02/form3-02292024_090209.xml 0001415889-24-005874 10180
2024-02-29 SC 13G/A SC 13G/A 0001104659-24-029377 005-93800 24703837 34 233113
2024-02-27 4 FORM 4 0001894562-24-000016 5734
2024-02-23 4 FORM 4 0001894562-24-000014 5406
2024-02-23 4 FORM 4 0001894562-24-000013 5407
2024-02-23 4 FORM 4 0001894562-24-000012 5396
2024-02-23 4 FORM 4 0001894562-24-000011 5422
2024-02-23 4 FORM 4 0001894562-24-000010 5437
2024-02-22 SC 13D ARCH VENTURE FUND XII, L.P. - PRIME MEDICINE -- SCH 13D 0001072613-24-000265 005-93800 24667079 34 448606
2024-02-20 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-003740 10427
2024-02-20 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-003739 12576
2024-02-20 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-003738 20342
2024-02-16 8-K 8-K 1.01,9.01 0001193125-24-038016 001-41536 24645712 34 554809 1 1
2024-02-16 424B5 424B5 0001628280-24-005201 333-275321 24645704 33 1312182
2024-02-15 FWP FWP 0001628280-24-004927 333-275321 24641872 34 145295
2024-02-14 424B5 424B5 0001628280-24-004859 333-275321 24640781 33 1272956
2024-02-14 8-K 8-K 2.02 0001628280-24-004785 001-41536 24638251 34 158623 1 1
2024-02-09 SC 13G/A SC 13G/A 0001104659-24-012941 005-93800 24614902 34 177037
2024-02-09 SC 13G/A filing.txt 0000315066-24-001470 005-93800 24612077 34 7883
2024-01-19 4 FORM 4 0001894562-24-000004 5417
2024-01-19 3 FORM 3 0001894562-24-000003 7530
2024-01-08 8-K 8-K 7.01,9.01 0001193125-24-003924 001-41536 24518401 34 14938724 1 1
2024-01-05 8-K 8-K 8.01 0001628280-24-000676 001-41536 24517393 34 152759 1 1
2024-01-05 8-K 8-K 5.02,9.01 0001628280-24-000524 001-41536 24514483 34 290637 1 1
2023-11-14 4 FORM 4 0001894562-23-000034 8573
2023-11-13 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-11-13 16:01:00 9999999995-23-003310 333-275321 231401271 33 1665
2023-11-09 CORRESP filename1.htm 0001193125-23-274699 6239
2023-11-07 UPLOAD filename1.pdf 0000000000-23-012206 40136
2023-11-03 S-3 S-3 0001628280-23-036792 333-275321 231377419 33 1597527
2023-11-03 10-Q 10-Q 0001628280-23-036777 001-41536 231377295 34 4983174 1 1
2023-11-03 8-K 8-K 2.02,9.01 0001628280-23-036706 001-41536 231376333 34 245313 1 1
2023-08-07 10-Q 10-Q 0001628280-23-027772 001-41536 231147694 34 17155188 1 1
2023-08-07 8-K 8-K 2.02,7.01,9.01 0001628280-23-027756 001-41536 231147528 34 5731894 1 1
2023-07-26 4/A FORM 4/A 0001894562-23-000032 4803
2023-07-25 4 FORM 4 0001894562-23-000030 4439
2023-06-22 4 FORM 4 SUBMISSION 0001209191-23-039122 24320
2023-06-20 144 xsl144X01/primary_doc.xml 0001974078-23-000075 001-41536 231026107 33 16971
2023-06-20 4 FORM 4 SUBMISSION 0001209191-23-038363 24319
2023-06-16 4 FORM 4 0001894562-23-000028 5352
2023-06-16 4 FORM 4 0001894562-23-000027 5369
2023-06-16 4 FORM 4 0001894562-23-000026 5381
2023-06-16 4 FORM 4 0001894562-23-000025 5351
2023-06-16 4 FORM 4 0001894562-23-000024 5372
2023-06-16 4 FORM 4 0001894562-23-000023 5348
2023-06-16 8-K 8-K 5.07 0001628280-23-022447 001-41536 231020886 34 182626 1 1
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037334 24320
2023-06-13 4 FORM 4 SUBMISSION 0001209191-23-036666 24321
2023-06-12 144 xsl144X01/primary_doc.xml 0001974078-23-000065 001-41536 231008862 33 13391
2023-06-09 4 FORM 4 SUBMISSION 0001209191-23-035849 24322
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035068 24313
2023-06-05 144 xsl144X01/primary_doc.xml 0001974078-23-000056 001-41536 23993506 33 10373
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033697 26295
2023-05-31 4 FORM 4 SUBMISSION 0001209191-23-033107 24315
2023-05-30 144 xsl144X01/primary_doc.xml 0001974078-23-000054 001-41536 23977242 33 9196
2023-05-26 4 FORM 4 SUBMISSION 0001209191-23-032529 24311
2023-05-24 4 FORM 4 SUBMISSION 0001209191-23-031916 24315
2023-05-22 4 FORM 4 SUBMISSION 0001209191-23-031450 26293
2023-05-18 144 xsl144X01/primary_doc.xml 0001974078-23-000039 001-41536 23936501 33 9843
2023-05-18 4 FORM 4 SUBMISSION 0001209191-23-030621 19656
2023-05-17 8-K 8-K 7.01,9.01 0001628280-23-018552 001-41536 23929617 34 213430 1 1
2023-05-16 4 FORM 4 SUBMISSION 0001209191-23-029789 19655
2023-05-12 4 FORM 4 0001894562-23-000014 5292
2023-05-12 3 FORM 3 0001894562-23-000013 7729
2023-05-12 4 FORM 4 SUBMISSION 0001209191-23-029033 21634
2023-05-11 10-Q 10-Q 0001628280-23-017423 001-41536 23908988 34 5311738 1 1
2023-05-11 DEFA14A DEFA14A 0001628280-23-017421 001-41536 23908950 34 33443
2023-05-11 8-K 8-K 5.02 0001628280-23-017420 001-41536 23908946 34 176371 1 1
2023-05-11 8-K 8-K 2.02,9.01 0001628280-23-017419 001-41536 23908942 34 246932 1 1
2023-05-10 4 FORM 4 SUBMISSION 0001209191-23-028464 24057
2023-05-08 144 xsl144X01/primary_doc.xml 0001974078-23-000006 001-41536 23899152 33 5404
2023-04-28 ARS ARS 0001628280-23-013832 001-41536 23860622 34 20865441
2023-04-28 DEFA14A DEFA14A 0001628280-23-013821 001-41536 23860572 34 458197
2023-04-28 DEF 14A DEF 14A 0001628280-23-013811 001-41536 23860549 34 519282
2023-04-20 4 FORM 4 0001894562-23-000010 5328
2023-04-20 4 FORM 4 0001894562-23-000008 5390
2023-04-04 4 FORM 4 0001894562-23-000006 5392
2023-04-04 4 FORM 4 0001894562-23-000005 5377
2023-04-04 4 FORM 4 0001894562-23-000004 5376
2023-04-04 4 FORM 4 0001894562-23-000003 5410
2023-04-04 4 FORM 4 0001894562-23-000002 5366
2023-04-04 4 FORM 4 0001894562-23-000001 5390
2023-03-10 8-K/A 8-K/A 2.02,9.01 0001193125-23-066791 001-41536 23721667 34 231438 1 1
2023-03-09 S-8 S-8 0001628280-23-007302 333-270400 23719978 33 126381
2023-03-09 10-K 10-K 0001628280-23-007266 001-41536 23719367 34 166316539 1 1
2023-03-09 8-K 8-K 2.02,9.01 0001193125-23-065373 001-41536 23718275 34 223754 1 1
2023-02-13 SC 13G ARCH VENTURE FUND X, L.P. - PRIME MEDICINE, INC. -- SCH 13G 0001072613-23-000104 005-93800 23618428 34 298173
2023-02-10 SC 13G SC 13G 0001104659-23-018498 005-93800 23611781 34 218455
2023-02-09 SC 13G/A filing.txt 0000315066-23-001354 005-93800 23601211 34 7750
2023-02-07 SC 13G SC 13G 0001193125-23-027015 005-93800 23595721 34 81739
2023-01-09 8-K FORM 8-K 7.01,9.01 0001193125-23-004734 001-41536 23518094 34 9904417 1 1
2022-11-14 10-Q 10-Q 0001628280-22-029889 001-41536 221386881 34 8081636 1 1
2022-10-26 4 FORM 4 0001628280-22-027126 24597
2022-10-26 4 FORM 4 0001628280-22-027125 32398
2022-10-26 4 FORM 4 0001628280-22-027124 24036
2022-10-26 4 FORM 4 0001628280-22-027123 6880
2022-10-26 4 FORM 4 0001628280-22-027122 11773
2022-10-26 4 PRIMARY DOCUMENT 0000315066-22-001801 24903
2022-10-26 SC 13G filing.txt 0000315066-22-001800 005-93800 221331692 34 7505
2022-10-24 8-K 8-K 5.03,9.01 0001628280-22-026895 001-41536 221326383 34 207829
2022-10-24 3/A FORM 3/A 0001628280-22-026890 4883
2022-10-21 424B4 424B4 0001628280-22-026826 333-267579 221324200 33 95409289
2022-10-21 4 FORM 4 0001628280-22-026824 5248
2022-10-21 4 FORM 4 0001628280-22-026823 5281
2022-10-21 4 FORM 4 0001628280-22-026822 5272
2022-10-20 FWP FWP 0001628280-22-026673 333-267579 221319505 34 8863
2022-10-19 SEC STAFF LETTER filename1.pdf 9999999997-22-004558 275198
2022-10-19 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2022-10-19 16:00:00 9999999995-22-003086 333-267579 221319663 33 1665
2022-10-19 3 PRIMARY DOCUMENT 0000315066-22-001797 11228
2022-10-19 3 FORM 3 0001628280-22-026690 7473
2022-10-19 3 FORM 3 0001628280-22-026689 26177
2022-10-19 3 FORM 3 0001628280-22-026688 17787
2022-10-19 3 FORM 3 0001628280-22-026687 8954
2022-10-19 3 FORM 3 0001628280-22-026686 8852
2022-10-19 3 FORM 3 0001628280-22-026685 10020
2022-10-19 3 FORM 3 0001628280-22-026684 10923
2022-10-19 3 FORM 3 0001628280-22-026683 9520
2022-10-19 3 FORM 3 0001628280-22-026682 10166
2022-10-19 3 FORM 3 0001628280-22-026681 11448
2022-10-19 3 FORM 3 0001628280-22-026680 12358
2022-10-19 3 FORM 3 0001628280-22-026679 8801
2022-10-19 3 FORM 3 0001628280-22-026678 14048
2022-10-19 3 FORM 3 0001628280-22-026677 11071
2022-10-19 3 FORM 3 0001628280-22-026676 9514
2022-10-19 S-1MEF S-1MEF 0001628280-22-026665 333-267954 221319452 33 72370
2022-10-19 S-8 S-8 0001628280-22-026643 333-267953 221319289 33 107924
2022-10-19 CERT 8A_Cert_PRME.pdf 0001354457-22-000578 001-41536 221317550 34 185812
2022-10-17 8-A12B 8-A12B 0001628280-22-026508 001-41536 221314161 34 18318
2022-10-17 CORRESP filename1.htm 0001628280-22-026501 19623
2022-10-17 CORRESP filename1.htm 0001628280-22-026500 12702
2022-10-17 FWP FWP 0001628280-22-026499 333-267579 221313799 34 8963
2022-10-17 CORRESP filename1.htm 0001628280-22-026492 13572
2022-10-17 S-1/A S-1/A 0001628280-22-026491 333-267579 221313512 33 95519488
2022-10-14 UPLOAD filename1.pdf 0000000000-22-011336 44159
2022-10-13 CORRESP filename1.htm 0001628280-22-026331 16177
2022-10-13 S-1/A S-1/A 0001628280-22-026329 333-267579 221308401 33 98631141
2022-10-07 CORRESP filename1.htm 0001628280-22-026153 28858
2022-09-30 UPLOAD filename1.pdf 0000000000-22-010796 46046
2022-09-23 S-1 S-1 0001628280-22-025424 333-267579 221262475 33 102400306
2022-08-05 DRS/A filename1.htm 0001628279-22-000370 377-05831 221140579 33 96546228
2022-05-06 DRS/A filename1.htm 0001628279-22-000257 377-05831 22901108 33 75141918
2022-04-11 SEC STAFF LETTER filename1.pdf 9999999997-22-001572 275980
2022-04-08 DRSLTR filename1.htm 0001628279-22-000192 17536
2022-04-08 DRS/A filename1.htm 0001628279-22-000190 377-05831 22816827 33 74417487
2022-03-30 UPLOAD filename1.pdf 0000000000-22-003481 46527
2022-03-25 DRSLTR filename1.htm 0001628279-22-000146 27045
2022-03-25 DRS/A filename1.htm 0001628279-22-000144 377-05831 22771224 33 74234408
2022-03-15 UPLOAD filename1.pdf 0000000000-22-002823 50159
2022-03-07 DRSLTR filename1.htm 0001628279-22-000119 67690
2022-03-07 DRS/A filename1.htm 0001628279-22-000118 377-05831 22719210 33 75085111
2022-02-17 UPLOAD filename1.pdf 0000000000-22-001948 72114
2022-02-04 DRSLTR filename1.htm 0001628279-22-000058 185012
2022-02-04 DRS/A filename1.htm 0001628279-22-000057 377-05831 22594408 33 76402604
2022-01-18 UPLOAD filename1.pdf 0000000000-22-000596 83125
2022-01-12 DRS/A filename1.htm 0001628279-22-000012 377-05831 22526198 33 3299727
2021-12-20 DRS filename1.htm 0001628279-21-000794 377-05831 211506054 33 55802822

Latest XBRL company facts

One latest value per concept from companyfacts (215 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 181.92M 2026-10-31 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
dei EntityPublicFloat Entity Public Float USD 238.76M 2025-06-30 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 6.39M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AccountsReceivableGrossCurrent Accounts Receivable, before Allowance for Credit Loss, Current USD 120,000 2025-06-30 2025 Q2 10-Q 2025-08-07 0001628280-25-038619
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 300,000 2022-09-30 2022 Q3 10-Q 2022-11-14 0001628280-22-029889
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 10.85M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 5.58M 2024-09-30 2024 Q3 10-Q 2024-11-12 0001628280-24-047130
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 25.83M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -3,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 1.03B 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition USD 338,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD 4.80M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 18.80M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 14.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 25.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap Assets Assets USD 213.85M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AssetsCurrent Assets, Current USD 63.69M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 60.63M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 3,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 6.27M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value USD 98.47M 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 6.27M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 6.27M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 6.27M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001628280-26-053883
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 54.89M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 61.20M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 68.58M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -8.15M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 120.50M 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 7.62M 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 775.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 181.39M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 181.39M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap CommonStockValue Common Stock, Value, Issued USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -130.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 8.98M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 50.78M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-28 0001628280-25-008884
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-07 0001628280-25-038619
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 34.49M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredIncomeTaxLiabilitiesNet Deferred Income Tax Liabilities, Net USD 134,000 2024-03-31 2024 Q1 10-Q 2024-05-10 0001628280-24-022473
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-28 0001628280-25-008884
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 273.90M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 50.09M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 116.78M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration USD 429.23M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration USD 421.88M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 0 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 30.00M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 11.31M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 19.83M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 239.41M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 100,000 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0001628280-22-029889
us-gaap DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay pure 0.06 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.5 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 5.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap DividendsPreferredStockCash Dividends, Preferred Stock, Cash USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.73 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.73 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.223 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.009 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.003 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.006 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.026 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.023 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 5.34M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap EquitySecuritiesFvNi Equity Securities, FV-NI USD 5.45M 2023-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap EquitySecuritiesFvNiCost Equity Securities, FV-NI, Cost USD 5.49M 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap EquitySecuritiesFvNiUnrealizedGain Equity Securities, FV-NI, Unrealized Gain USD 2.35M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap EquitySecuritiesFvNiUnrealizedGainLoss Equity Securities, FV-NI, Unrealized Gain (Loss) USD 1.70M 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-11 0001628280-23-017423
us-gaap EquitySecuritiesFvNiUnrealizedLoss Equity Securities, FV-NI, Unrealized Loss USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-28 0001628280-25-008884
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 38.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ImpairmentOfLongLivedAssetsToBeDisposedOf Impairment of Long-Lived Assets to be Disposed of USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap IncomeLossAttributableToParent Income (Loss) Attributable to Parent, before Tax USD -104.48M 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-07 0001628280-25-038619
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 44.87M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -42.24M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 291,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 633,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 1.02M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 4.63M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -2.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001628280-26-053883
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD -1.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -6.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap IncreaseDecreaseInEquitySecuritiesFvNi Increase (Decrease) in Equity Securities, FV-NI USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -6.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 1.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap IncrementalCommonSharesAttributableToCallOptionsAndWarrants Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants shares 3.20M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 2.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LeaseCost Lease, Cost USD 33.99M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 168.19M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 74.48M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 22.36M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 22.12M 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 22.12M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 21.48M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 22.29M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 5.46M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 57.76M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap Liabilities Liabilities USD 205.42M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 213.85M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LiabilitiesCurrent Liabilities, Current USD 35.63M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap LiabilitiesFairValueDisclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure USD 12.02M 2021-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value USD 43.50M 2023-10-01 2023-10-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap LossContingencyReceivable Loss Contingency, Receivable USD 10.80M 2024-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 3.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 108.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -120.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -130.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -130.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -130.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 3.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OperatingExpenses Operating Expenses USD 140.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -133.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OperatingLeaseCost Operating Lease, Cost USD 22.96M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 110.42M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 9.41M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 101.01M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 117.58M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 8.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 1.00M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.122 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.02M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OtherAssetsCurrent Other Assets, Current USD 376,000 2026-06-30 2026 Q2 10-Q 2026-08-06 0001628280-26-053883
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 3.28M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -85,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -357,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 0 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-11 0001628280-23-017423
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 160,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 10.10M 2024-02-01 2024-02-29 2024 FY 10-K 2025-02-28 0001628280-25-008884
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 558,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 31.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap PreferredStockConvertibleSharesIssuable PreferredStockConvertibleSharesIssuable shares 51.92M 2021-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap PreferredStockDividendsIncomeStatementImpact Preferred Stock Dividends, Income Statement Impact USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 19.21M 2023-09-30 2023 Q3 10-Q 2023-11-03 0001628280-23-036777
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 2.53M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap PrepaidRent Prepaid Rent USD 100,000 2021-01-01 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 2.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments Proceeds from Maturities, Prepayments and Calls of Short-term Investments USD 140.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ProceedsFromSaleOfOtherInvestments Proceeds from Sale of Other Investments USD 5.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 470,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 41.45M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 15.62M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party USD 300,000 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-11 0001628280-23-017423
us-gaap RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty Related Party Transaction, Other Revenues from Transactions with Related Party USD 126,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 101.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 0 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap RestrictedCash Restricted Cash USD 13.69M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 13.69M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.02B 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 6.22M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Sale of Stock, Number of Shares Issued in Transaction shares 43.70M 2025-08-01 2025-08-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 3.3 2025-08-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 14.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 1.53M 2023-06-30 2023 Q2 10-Q 2023-08-07 0001628280-23-027772
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 4.08 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 1.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 7.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 21.39M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 3.55 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number shares 10.31M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 21.39M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 3.55 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 5.10M 2025-08-01 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 3.54 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 5.87 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 3.55 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 1.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 8.44M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.322 2022-10-01 2022-10-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross shares 2.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 132,617 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 395.80M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-01 0001628280-24-008116
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 138.38M 2025-07-01 2025-09-30 2025 Q3 10-Q 2025-11-07 0001628280-25-050422
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 0 2025-07-01 2025-09-30 2025 Q3 10-Q 2025-11-07 0001628280-25-050422
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 54,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap SubleaseIncome Sublease Income USD 212,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap TemporaryEquityAccretionToRedemptionValue Temporary Equity, Accretion to Redemption Value USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 395.80M 2021-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 335.81M 2021-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 161.42M 2021-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 161.42M 2021-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 161.42M 2021-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap UnrealizedGainLossOnInvestments Unrealized Gain (Loss) on Investments USD 357,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-09 0001628280-23-007266
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount Unrecorded Unconditional Purchase Obligation USD 136.64M 2024-09-30 2024 Q3 10-Q 2024-11-12 0001628280-24-047130
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 59.64M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap VariableLeaseCost Variable Lease, Cost USD 9.45M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001628280-26-013569
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 3.20M 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-08 0001628280-25-023486
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 177.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 177.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001628280-26-073392

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →